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Introduction
Rheumatic fever (RF) is a nonsuppurative sequela of
group-A streptococcal pharyngitis with multiple clini-
cal manifestations including carditis, arthritis, chorea,
subcutaneous nodules, and erythema marginatum (1).
Although arthritis is the most common manifestation,
carditis is the most serious and can lead to valvular scar-
ring. Finding the presence of antibody and complement
in heart and valve tissue of RF patients suggested that
rheumatic carditis was immunopathologically mediat-
ed (2–4). Group-A streptococci induce anti-heart anti-
bodies, and anti-myosin antibodies have been demon-
strated in the sera of patients with RF (5–8). Elevated
anti-streptococcal antibody responses against the
group-A streptococcal carbohydrate antigen persisted
in patients with RF and valvular heart disease (9). Fur-
thermore, an immunologic relationship between the
group-A polysaccharide and structural glycoproteins of
the heart valve was reported (10). Cross-reactive human
and murine mAbs identified streptococcal antigens M
protein (8, 11, 12) and N-acetyl- b D-glucosamine (Glc-
NAc) (13, 14), the immunodominant epitope of the
group-A streptococcal carbohydrate that share cross-
reactive epitopes with myosin, tropomyosin, keratin,
vimentin, and laminin (11, 12, 15–20). Importantly,
human mAbs produced from patients with RF reacted
with GlcNAc (5, 8, 14, 21), supporting the evidence that
anti-carbohydrate antibodies play a role in immuno-
logical cross-reactivity. Molecular mimicry between the
streptococcal carbohydrate GlcNAc and host antigens
may be important in rheumatic valvulitis and in the
generation of anti-myosin/anti-GlcNAc antibodies pres-
ent in patients with disease. Since it has not been deter-
mined how cross-reactive antibodies produce tissue
injury, our study focused on determining how mAb
3.B6 from a RF patient might produce cellular injury in
rheumatic carditis. Monoclonal antibody 3.B6 reacted
with valvular endothelium and laminin, an extracellu-
lar matrix protein present in the basement membrane
underlying endothelium of heart valves, and was cyto-
toxic for human umbilical vein endothelial (HUVE)
cells. Human cardiac myosin > laminin > GlcNAc and a
peptide from laminin A chain inhibited the reaction of
mAb 3.B6 with the valve. These data support the
hypothesis that anti-streptococcal/anti-myosin anti-
bodies in RF may produce cellular injury at the valvular
endothelium and finally link together anti-myosin reac-
tivity with the valve. Monoclonal antibody 3.B6 pro-
vides insight to our understanding of how antibodies in
patients with RF may recognize the valve surface and
increase the risk of rheumatic heart disease.
Methods
Hybridoma production
Peripheral blood was obtained from a 14-year-old male
diagnosed with RF using the Jones criteria. At the time
of blood collection the patient had carditis, heart mur-
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Anti-streptococcal antibodies cross-reactive with N-acetyl-b D-glucosamine (GlcNAc) and myosin are
present in the sera of patients with rheumatic fever (RF). However, their role in tissue injury is not
clear. In this study, we show that anti-GlcNAc/anti-myosin mAb 3.B6 from a rheumatic carditis
patient was cytotoxic for human endothelial cell lines and reacted with human valvular endotheli-
um and underlying basement membrane. Reactivity of mAb 3.B6 with the valve was inhibited by
human cardiac myosin > laminin > GlcNAc. The mAb 3.B6 epitopes were localized in fragments of
human cardiac myosin, including heavy meromyosin (HMM), the S1 subfragment, and two light
meromyosin (LMM) peptides containing amino acid sequences KEALISSLTRGKLTYTQQ (LMM 1)
and SERVQLLHSQNTSLINQK (LMM 33). A novel feature of mAb 3.B6 was its reactivity with the
extracellular matrix protein laminin, which may explain its reactivity with the valve surface. A laminin
A-chain peptide (HTQNT) that includes homology to LMM33 inhibited the reactivity of mAb 3.B6
with human valve. These data support the hypothesis that cross-reactive antibodies in rheumatic
carditis cause injury at the endothelium and underlying matrix of the valve.
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mur, polymigrating arthritis, and anti–streptolysin O
titer of 833. Mononuclear cells were separated from
whole blood by Histopaque-1077 Hybri-Max (Sigma
Chemical Co., St. Louis, Missouri, USA) and stimulated
for 1 week with streptococcal peptido-glycan-polysac-
charide (PG-PS) complexes (10 m g/mL) in Iscove’s mod-
ified Dulbecco’s medium (IMDM) containing 10%
human AB serum. The cells were stimulated with poke-
weed mitogen (1 m g/mL) in IMDM containing 10%
human AB serum for an additional week. Cells were
washed three times in IMDM without serum and fused
with HMMA2.11TG/0 cells (human/mouse myeloma
cell line; generous gift from Marshall Posner, Dana Far-
ber Cancer Institute, Boston, Massachusetts, USA) using
PEG-1000, as described previously (22). Hybridomas
were selected by culture in HAT medium and screened
using GlcNAc conjugated to BSA as described (21).
Cloning of hybridomas was achieved by limiting dilu-
tion and was performed three times. Established clones
were maintained in IMDM containing 20% FBS.
Nucleotide sequences of mAb 3.B6 V genes have been
reported previously (23).
Antigens
The following antigens were used to test specificity of
human mAb 3.B6: laminin (Sigma Chemical Co.), rM6
(generous gift from Vincent Fischetti, Rockefeller Univer-
sity, New York, New York, USA), GlcNAc-BSA (13), and
BSA (Fisher Biotech, Fairlawn, New Jersey, USA). Purity
was assessed using SDS-PAGE. Overlapping synthetic
peptides corresponding to the light meromyosin (LMM)
region of human cardiac myosin beta chain (HCM beta
chain) and two peptides from laminin A chain
(DRDQLM) (peptide 1) and HTQNT (peptide 2) were
generated on a Dupont RAMPS manual peptide synthe-
sizer using the f-moc strategy (24). The sequences and des-
ignations of the LMM peptides are as follows: LMM-1,
KEALISSLTRGKLTYTQQ; LMM-2 TYTQQLEDLKRQLE-
EEVK; LMM-3, EEEVKAKNALAHALQSAR; LMM-4,
LQSARHDCDLLREQYEEE; LMM-5, EQYEEETEAKAELQR-
VLSK; LMM-6, RVLSKANSEVAQWRTKYE; LMM-7, RTKYET-
DAIQRTEELEEA; LMM-8, ELEEAKKKLAQRLQEAEE; LMM-9,
QEAEEAVEAVNAKCSSLE; LMM-10, CSSLEKTKHRLQN-
EIEDL; LMM-11, EIEDLMVDVERSNAAAAA; LMM-12,
AAAAALDKKQRNFDKILA; LMM-13, DKILAEWKQKY-
EESQSEL; LMM-14, SQSELESSQKEARSLSTE; LMM-15,
SLSTELFKLKNAYEESLE; LMM-16, EESLEHLETFKRENKN-
LQ; LMM-17, NKNLQEEISDLTEQLGSS; LMM-18, EQLGSS-
GKTIHELEKVRKQ; LMM-19, KVRKQLEAEKMELQSALE;
LMM-20, LQSALEEAEASLEHEEGKI; LMM-21, EEGKIL-
RAQLEFNQIKAE; LMM-22, NQIKAEIERKLAEKDEEME;
LMM-23, DEEMEQAKRNHLRVVDSL; LMM-24, VVDSLQT-
SLDAETRSRNE; LMM-25, RSRNEALRVKKKMEGDLN; LMM-
26, EGDLNEMEIQLSHANRMA; LMM-27, ANRMAAE-
AQKQVKSLQSL; LMM-28, SLQSLLKDTQIQLDDAVR;
LMM-29, RANDDLKENIAIVERRNN; LMM-30, IAIVERRNNL-
LQAELEEL; LMM-31, ELEELRAVVEQTERSRKL; LMM-32,
RSRKLAEQELIETSERVQ; LMM-33, SERVQLLHSQNTSLIN-
QK; LMM-34, LINQKKKMDADLSQLQTE; LMM-35, TEV-
EEAVQESRNAEEKAKK; LMM-36, RNAEEKAKKAITDAAM-
MA; LMM-37, AAMMAEELKKEQDTSAHL; LMM-38, TSAH-
LERMKKNMEQTIKDL; LMM-39, TIKDLQHRLDEAEQIALK;
LMM-40, EQIALKGGKKQLQKLEARV; LMM-41, LEARVRE-
LENELEAEQKR; LMM-42, AEQKRNAESVKGMRKSER; LMM-
43, RKSERRIKELTYQTEEDR; LMM-44, TEEDRKNLLR-
LQDLVDKL; LMM-45, LVDKLQLKVKAYKRQAEE; LMM-46,
RQAEEAEEQANTNLSKFR; LMM-47, LSKFRKVQHELD-
EAEERA; LMM-48, AEERADIAESQVNKLRAK; and LMM-49,
KLRAKSRDIGTKGLNEE.
Purification of HCM, subfragment 1, 
and heavy meromyosin 
HCM. HCM was purified from human heart tissue
according to Tobacman et al. (25), with slight modifica-
tions. Heart tissue was homogenized in low-salt buffer
(40 mM KCl, 20 mM imidazole, pH 7.0, 5 mM EGTA, 5
mM DTT, 0.5 mM PMSF, and 1 m g/mL leupeptin) on ice
for 15 seconds. Washed myofibrils were collected by cen-
trifugation at 16,000 g for 10 minutes. Pellets were resus-
pended in high-salt buffer (0.3 M KCl, 0.15 M K2HPO4,
1 mM EGTA, 5 mM DTT, 0.5 mM PMSF, and 1 m g/mL
leupeptin), homogenized, and incubated on ice, stirring
for 30 minutes to facilitate acto-myosin extraction. After
centrifugation, acto-myosin was precipitated by adding
10 volumes of cold water followed by a pH adjustment
to 6.5. DTT was increased to 5 mM, and precipitation
was allowed to proceed for 30 minutes. Acto-myosin was
pelleted by centrifugation at 16,000 g. The acto-myosin
pellet was resuspended in high-salt buffer, ammonium
sulfate added to 33%, and KCl concentration increased
to 0.5 M. After the acto-myosin pellet was dissolved, ATP
was added to reach 10 mM, MgCl2 added to reach 5 mM,
and the solution centrifuged at 20,000 g for 15 minutes
to remove actin filaments. The supernatant was stored
at 4°C with protease inhibitors: 0.5 mM PMSF, 5 m g/mL
TLCK, and 1 m g/mL leupeptin. 
Subfragment-1. At lower ionic strength, chymotryptic
cleavage yields subfragment-1 (S1) and myosin rod, and
at higher ionic strength, chymotryptic cleavage yields
heavy meromyosin (HMM) and light meromyosin
(LMM). Further cleavage of HMM yields S1 and S2 sub-
fragments. S1 was produced from purified HCM accord-
ing to Tobacman et al., with slight modification (25).
Myosin was dialyzed against digestion buffer (0.1 M
NaCl, 0.01 M imidazole-HCl, pH 7, and 0.001 M DTT),
and cleaved with a 1:100 wt/wt ratio of a -chymotrypsin
to myosin for 15 minutes at 25°C. The reaction was ter-
minated by the addition of PMSF to a final concentra-
tion of 0.3 mM. Rod and uncleaved myosin were precip-
itated by dialysis in a low-salt solution (10 mM NaCl, 10
mM imidazole, pH 7.0, 1 mM DTT) and separated from
soluble S1 by centrifugation at 200,000 g. S1 purity was
assessed using SDS-PAGE, and in some cases S1 was
purified by ammonium sulfate precipitation and/or
DEAE ion-exchange chromatography. 
HMM subfragment. HMM subfragment of HCM was
prepared according to a described procedure with
slight modification (26). HMM was prepared by digest-
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ing myosin in 0.6 M KCl, 2 mM MgC12, 1 mM DTT,
and 0.01 M Tris-HCl (pH 7.6), with 1:100 wt/wt ratio of
a -chymotrypsin to myosin for 10 minutes at 25°C. The
reaction was terminated by adding PMSF to a final
concentration of 0.3 mM. LMM and uncleaved myosin
were precipitated by dialysis in low salt (0.03 M KCl,
0.01 M potassium phosphate, pH 6.3, 1 mM DTT, and
1 mM MgCl2) and separated from soluble HMM by
centrifugation at 200,000 g. HMM purity was assessed
using SDS-PAGE. In some cases HMM was purified by
ammonium sulfate precipitation and/or DEAE ion-
exchange chromatography.
ELISA
Antigens were coated onto Immunolon 4 ELISA plates
(Dynatech Laboratories, Chantilly, Virginia, USA) at 10
m g/mL in 0.015 M carbonate/0.03 M bicarbonate (pH 9.6)
buffer overnight at 4°C. After two washes with PBS con-
taining 0.05% Tween (PBS-Tween), wells were blocked
with 1% BSA in PBS for 1 hour at 37°C. Wells were washed
two times with PBS-Tween, and mAb (10 m g/mL) was
incubated overnight at 4°C. After three PBS-Tween wash-
es, alkaline phosphatase–labeled goat anti-human IgM
(1:500; Sigma Chemical Co.) was incubated in the wells for
1 hour at 37°C. Finally, 50 m L substrate, p-nitrophenyl
phosphate (Sigma 104 phosphatase substrate), prepared
in diethanolamine buffer at 1 mg/mL was added. OD was
measured at 405 nm with an automated ELISA reader
(Dynatech MR 700). Results were expressed as the mean
of triplicate wells.
Competitive-inhibition ELISA
Competitive-inhibition ELISA was performed in tripli-
cate as described (11, 27). Inhibitor solutions (HCM, Glc-
NAc-BSA, BSA, or laminin) were prepared in PBS and
mixed with an equal volume of mAb 3.B6 (10 m g/mL),
incubated at 37°C for 1 hour and overnight at 4°C. Fifty
microliters of mAb 3.B6 mixture was added to wells coat-
ed with HCM, GlcNAc-BSA, or BSA (10 m g/mL). The
remainder of the assay was performed as described
above. Percentage of inhibition was calculated as follows:
100 · (1-[A410 inhibitor + mAb 3.B6/A410 PBS + mAb
3.B6]). Maximal (100%) reactivity was determined by
incubating mAb 3.B6 with PBS without inhibitor.
Dot blot
Fifty micrograms of each peptide or protein was applied
to nitrocellulose membrane using a vacuum dot-blot
apparatus (Bio-Rad Laboratories, Hercules, California,
USA). The membrane was blocked with 5% skim milk
for 3 hours at 37°C, washed twice with PBS-Tween, and
incubated overnight at 4°C with mAb 3.B6. After 5 PBS-
Tween washes, the membrane was incubated with
horseradish peroxidase–conjugated goat anti-human
IgM (diluted 1:250; Sigma Chemical Co.) for 1 hour at
37°C, and washed 5 times with PBS-Tween, followed by
a wash with 0.05 M Tris (pH 7.5). Finally, 0.25 mg/mL
alpha-chloronapthol (Sigma Chemical Co.) and 17 m L
of 30% hydrogen peroxide in 100 mL of 0.05 M Tris
buffer was used as substrate to detect mAb 3.B6-reactive
peptides. Negative control wells were BSA or PBS.
Immunohistochemistry staining of human valves
and myocardium
Human mitral valves and myocardium were fixed
overnight in 10% buffered formalin (Fisher Scientific,
Pittsburgh, Pennsylvania, USA), sectioned (4–5 m m
thick) and mounted on Microprobe ProbeOn Plus slides
(Fisher). Mounted tissues were baked at 60°C for 20
minutes and deparaffinized using a 3:1 ratio of Hemo-
D (Fisher) to xylene. After rehydration in graded ethanol
washes, tissues were washed twice with PBS, blocked
with Protein Blocker (BioGenex, San Ramon, California,
USA) for 15 minutes at room temperature, and washed
twice with PBS. Monoclonal antibody 3.B6 (10 m g/mL)
or isotype control human IgM antibody (10 m g/mL;
Sigma Chemical Co.) were incubated on tissues for 30
minutes at room temperature followed by three PBS
washes. Biotin-conjugated goat anti-human IgM anti-
bodies (diluted 1:500; Jackson ImmunoResearch, West
Grove, Pennsylvania, USA) were incubated on tissues for
30 minutes at room temperature, followed by three
washes in PBS. Alkaline phosphatase–conjugated strep-
tavidin (Jackson ImmunoResearch) was incubated on
the tissues at 1 m g/mL for 30 minutes at room tempera-
ture. After three washes in PBS, antibody binding was
detected with Fast Red substrate (BioGenex) against a
counterstain of Mayer’s hematoxylin (BioGenex).
Stained slides were mounted with crystal mount (Fish-
er), dried, and coverslipped using permount (Sigma
Chemical Co.) as the mounting media.
Competitive inhibition of reactivity of mAb 3.B6 with
human valve tissue sections
A competitive inhibition assay was used to test the
antigens HCM, laminin, GlcNAc-BSA, BSA alone, and
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Figure 1
Reactivity of human mAb 3.B6 with HCM, GlcNAc-BSA, and BSA in
the ELISA. Results shown as OD measured at 405 nm. Inset shows a
Western blot of HCM reacted with mAb 3.B6 (lane 2); Amido black
stain of HCM (lane 1) and negative control blot reacted with perox-
idase-conjugated anti-human IgM antibodies (lane 3) are also
shown. Molecular mass is indicated.
laminin A-chain peptides 1 and 2 for inhibition of mAb
3.B6 reactivity with human valve sections. Inhibitors
were mixed with mAb 3.B6 at a final concentration of
500 m g/mL and incubated at 37°C and overnight at
4°C before applying the mAb to tissue sections of
human valve. Detection of mAb binding to tissues was
performed as described above.
Cytotoxicity assay
HUVE cells were isolated and cultured in Medium 199
(GIBCO BRL, Grand Island, New York, USA) with 20%
FBS, 10 m g/mL endothelial cell growth factor (Sigma
Chemical Co.), 90 m g/mL porcine heparin (Sigma Chem-
ical Co.), and penicillin and streptomycin (GIBCO BRL),
as described previously (28). HUVE cells cultured in 96-
well flat-bottom plates at 2 · 104 cells/well overnight at
37°C and 5% CO2 were labeled for 2 hours with 5
m Ci/well of sodium chromate51 (Dupont NEN, Boston,
Massachusetts, USA). Labeled HUVE cells were washed
three times with Medium 199 containing 20% FBS and
incubated with the same media for an additional hour at
37°C and 5% CO2. After three washes with Medium 199
without FBS, mAb 3.B6 and IgM isotype controls were
added (100 m L/well) and cells incubated at 37°C for 1
hour. Then, 100 m L of guinea pig complement (Sigma
Chemical Co.) was added to each well followed by a 1-
hour incubation at 37°C. Supernatants were collected
from 96-well microtiter plates using the Skatron har-
vesting system (Skatron Inc., Sterling, Virginia, USA).
Counts per minute were determined by a 1282 Com-
pugamma counter (LKB Wallac, Gaithersburg, Mary-
land, USA). Percentage of lysis was calculated using the
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Figure 3
(a) Dose-response curve of mAb 3.B6 reacted with HCM, HCM subfragments (HMM and S1), GlcNAc-BSA, and BSA by ELISA. Although
mAb 3.B6 reacted with HCM, HMM, and GlcNAc, the strongest reactivity was with the S1 subfragment. (b) Reactivity of mAb 3.B6 with
human LMM peptides in the immunodot blot assay. Fifty micrograms of peptide were adsorbed onto nitrocellulose and reacted with mAb
3.B6 (10 m g/mL); mAb 3.B6 binding was detected by peroxidase-conjugated anti-human IgM antibodies. Samples were performed in dupli-
cate. PBS was the negative control in which no peptide was blotted onto nitrocellulose. Monoclonal antibody 3.B6 reacted with LMM 1,
LMM 33, and weakly with LMM 17, as shown.
Figure 2
Inhibition of mAb 3.B6 by HCM and GlcNAc-BSA.
Monoclonal antibody 3.B6 (10 m g/mL) was mixed
1:1 with increasing amounts of inhibitor (0 to 500
m g/mL), and binding of free mAb to immobilized
HCM (a) or GlcNAc-BSA (b) on the microtiter plate
was detected by ELISA. The concentration of HCM
required to inhibit 50% of binding of mAb 3.B6 to
GlcNAc-BSA was 67 m g/mL (b). The concentration
of GlcNAc-BSA required to inhibit 50% of binding of
mAb 3.B6 to HCM was more than 500 m g/mL (a).
BSA alone did not inhibit mAb 3.B6. Inhibitors are
as follows: squares, HCM; diamonds, GlcNAc-BSA;
circles, BSA. Percentage of inhibition was calculated
using the following formula: 100 · (1-[A410 inhibitor
+ mAb 3.B6/A410 PBS + mAb 3.B6]).
following equation: % lysis = [(test release – spontaneous
release) / (maximum release – spontaneous release)] ·
100. Spontaneous release was measured using IMDM
without antibody, and maximum release was measured
using 1 N HCl. Controls were three human IgM mAbs
without cytolytic activity against HUVE.
Results
Characterization of mAb 3.B6. Monoclonal antibody 3.B6
reacted with GlcNAc and cardiac myosin (Figure 1, inset,
lanes 1 and 2) and in previous studies reacted with
tropomyosin, vimentin, and weakly with keratin and
recombinant M6 protein (rM6) (23). Competitive-inhi-
bition ELISA was employed to determine avidity of mAb
3.B6 for HCM and GlcNAc. The concentration of HCM
that inhibited binding of mAb 3.B6 to GlcNAc-BSA by
50% was 67 m g/mL (Figure 2b), whereas a much higher
concentration of GlcNAc-BSA (> 1000 m g/mL) was
required to inhibit binding of mAb 3.B6 to HCM by 50%
(Figure 2a). The mAb 3.B6 binding avidity was HCM >
GlcNAc-BSA in the ELISA. Inhibition by BSA was less
than 10% at all concentrations tested (Figure 2, a and b).
To localize the mAb 3.B6 epitope(s) in HCM, S1 and
HMM subfragments, and LMM, peptides were reacted
with mAb 3.B6. S1 and HMM subfragments reacted
with mAb 3.B6 in the ELISA (Figure 3a), suggesting that
mAb 3.B6 recognized epitope(s) in both fragments.
However, mAb 3.B6 reacted with S1 more intensely than
intact HCM (Figure 3a). Monoclonal antibody 3.B6 was
tested for reactivity with 49 overlapping synthetic pep-
tides corresponding to the LMM rod region of HCM
(Figure 3b) and reacted with LMM 1 (residues
1295–1312), LMM 33 (amino acids 1711–1728), and
weakly with LMM 17 (residues 1503–1520; Figure 3b).
Reactivity of mAb 3.B6 with human valvular endothelium.
Experiments were performed to test the ability of mAb
3.B6 to react with human valvular endothelium. For-
malin-fixed normal human heart valves were reacted
with mAb 3.B6 using immunohistochemistry tech-
niques. Monoclonal antibody 3.B6 reacted intensely
with endothelial cells at the valve surface and the
underlying basement membrane/extracellular matrix
(Figure 4a). It also reacted with sections of human
myocardium (data not shown). Control sections of
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Figure 4
(a) Reactivity of mAb 3.B6 with normal human valve. Formalin-fixed human mitral valves were processed by routine histochemical tech-
niques and incubated with mAb 3.B6 at 10 m g/mL. Monoclonal antibody 3.B6 binding was detected using biotin-conjugated anti-human
antibodies and alkaline phosphatase–labeled streptavidin followed by phosphatase substrate. (b) Control valve sections were negative after
reaction with human IgM at 10 m g/mL.
Figure 5
(a) Inhibition of mAb 3.B6 binding to GlcNAc-BSA by laminin. Mon-
oclonal antibody 3.B6 (10 m g/mL) was mixed with increasing amounts
of inhibitor (0–500 m g/mL), and binding of mAb to GlcNAc-BSA on
the microtiter plate was detected by ELISA; mAb 3.B6 binding to BSA
coated wells was negative. Inhibitors are as follows: squares, laminin;
circles, BSA. Percentage of inhibition was calculated by the formula
used in Figure 2. (b) Reactivity of mAb 3.B6 with laminin in the immun-
odot blot assay. Fifty micrograms laminin was adsorbed onto nitro-
cellulose and reacted with mAb 3.B6 (10 m g/mL), and mAb 3.B6 bind-
ing to laminin was detected by peroxidase-conjugated anti-human IgM
antibodies followed by substrate. Monoclonal antibody 3.B6 did not
bind to BSA, and the IMDM medium control was not laminin reactive.
human valve and myocardium (not shown) were react-
ed with human IgM at the same concentration as mAb
3.B6 and were negative (Figure 4b).
Reactivity of mAb 3.B6 with laminin. Binding inhibition
assays were performed to determine if mAb 3.B6 could
recognize soluble extracellular matrix proteins such as
laminin. Soluble laminin inhibited mAb 3.B6 binding
to GlcNAc-BSA in a dose-dependent manner (Figure
5a). The mAb 3.B6 recognized laminin in the immun-
odot blot assay (Figure 5b). Comparison of 3.B6-posi-
tive LMM peptides with laminin revealed homology
between LMM33 and two different regions of the
laminin A chain shown in Figure 6.
Competitive inhibition of mAb 3.B6 reactivity with human
valve. HCM, laminin, GlcNAc-BSA, BSA, and laminin
A-chain peptides 1 and 2 were tested to determine their
capacity to inhibit binding of mAb 3.B6 to human
valve. Figure 7a illustrates binding of mAb 3.B6 with
valve and underlying matrix. Figure 7b illustrates inhi-
bition of mAb 3.B6 by HCM, and Figure 7c shows inhi-
bition by laminin. Figure 7d shows very weak inhibi-
tion by GlcNAc-BSA, and no inhibition by BSA alone
(not shown) was seen. Figure 7, e and f, respectively,
show that laminin A-chain peptide 1 did not inhibit
whereas peptide 2 did inhibit mAb 3.B6 binding to
valve. In summary, mAb 3.B6 valve reactivity was inhib-
ited by cardiac myosin > laminin > GlcNAc and by
laminin A-chain peptide 2.
Cytotoxic activity of mAb 3.B6 on HUVE cells. Since
human mAb 3.B6 reacted with valvular endothelium,
we investigated the possibility that mAb 3.B6 might be
cytotoxic for primary HUVE cells in the presence of
complement; mAb 3.B6 demonstrated 40% lysis of
HUVE cells in the presence of complement (Figure 8a).
Human IgM anti-streptococcal mAb 1.C8 did not pro-
duce lysis of the HUVE cells after addition of comple-
ment. Four other primary HUVE cell lines developed
were susceptible to lysis by mAb 3.B6 as compared with
the human IgM isotype control mAb 1.C8 (Figure 8b).
Discussion
We demonstrated previously that anti-streptococcal
mAbs are polyreactive and recognized streptococcal
and mammalian antigens (8, 11, 12, 16, 17, 20). Murine
anti-streptococcal antibodies were categorized into
three groups based on their antigen reactivity. Group 1
reacted with alpha-helical coiled-coil molecules such as
myosin, M protein, tropomyosin, and vimentin, where-
as group 2 was antinuclear and reacted with DNA and
myosin (11, 16, 29). Human anti-streptococcal mAbs
and antibodies in the sera of patients with RF are not
antinuclear and do not react with DNA (5, 8, 23). A
third group of cross-reactive anti-streptococcal murine
and human mAbs recognized GlcNAc, the immun-
odominant carbohydrate antigen of group A strepto-
cocci (13, 14, 21). The present work describes a novel
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Figure 6
Amino acid sequence alignment of laminin A chain and HCM LMM
33. Amino acid sequence designations of two homologous regions in
the laminin A chain are indicated above and HCM below in the figure.
The sequence of laminin A chain (44) and myosin heavy chain b (45)
have been described. The sequences shown are 64% identical and 91%
homologous. (:), Identity; (.), conserved amino acid substitution.
Figure 7
Competitive inhibition of mAb 3.B6 reactivity with human valve tissue sections. (a) Illustrates the reaction of mAb 3.B6 with valve endothe-
lium and underlying matrix; (b) inhibition of mAb 3.B6 by HCM; (c) inhibition of mAb 3.B6 by laminin; (d) very weak inhibition by GlcNAc-
BSA, whereas inhibition with BSA alone (not shown) was equivalent to Figure 7a; (e) no inhibition by laminin A-chain peptide DRDQLM
(residues 655–660); (f) inhibition by laminin A-chain peptide HTQNT (residues 1002–1006). Reactivity of mAb 3.B6 against human valve
was inhibited by cardiac myosin > laminin > GlcNAc, and laminin A-chain peptide HTQNT inhibited > laminin A-chain peptide DRDQLM .
anti-streptococcal/anti-myosin mAb (3.B6) produced
from a patient with active rheumatic carditis and
arthritis, which reacted with valvular endothelium and
was cytotoxic for human endothelial cells.
Other researchers have demonstrated the presence of
cytotoxic anti-endothelial cell antibodies in the serum
of patients with Kawasaki’s disease (30, 31, 32),
hemolytic-uremic syndrome (33), and individuals with
carotid atherosclerosis (34). Since mAb 3.B6 reacted
with human valve endothelium, we determined if mAb
3.B6 was cytotoxic for endothelial cells. Five HUVE cell
lines were susceptible to mAb 3.B6 lysis in the presence
of complement. Our data suggest that a human anti-
myosin antibody could potentially recognize surface
molecules on endothelial cells and valve.
Further evidence that mAb 3.B6 may be a potentially
damaging antibody at the valve surface is its recognition
of laminin, a glycoprotein located in basement mem-
brane underlying valvular endothelium (35). The
unique location of laminin in the extracellular matrix
and basement membrane makes it an ideal target for
polyreactive anti-streptococcal antibodies in rheumatic
carditis patients. Endothelial cell alterations may occur
under shear stress due to turbulent blood flow at the
valve surface (36, 37). Under these conditions, endothe-
lial alteration may result in exposure of the underlying
basement membrane/extracellular matrix. Exposure of
laminin may contribute to binding of cross-reactive
antibodies and subsequent inflammation of valvular
tissue in rheumatic patients. Indeed, scanning electron-
microscopy studies have demonstrated that valves from
patients with rheumatic heart disease have areas of
denuded endothelium resulting in exposure of the
subendothelial compartment (38). Laminin is secreted
by cultured endothelial cells (39), and it is possible that
mAb 3.B6 recognized laminin on their surface.
Monoclonal antibody 3.B6 recognized cardiac myosin
most strongly, and multiple epitopes were identified
within the HCM molecule as demonstrated by reactivi-
ty with S1, HMM, and two LMM peptides. Of particu-
lar interest was the reaction of mAb 3.B6 with peptide
LMM 33 of HCM. Peptide LMM 33 was found to con-
tain homologous amino acid sequences with the A
chain of laminin (Figure 7). Reaction of the two synthe-
sized peptide regions of the laminin A chain revealed
that peptide residues 1002–1006 inhibited the reaction
of mAb 3.B6 with valve endothelium and underlying
matrix. The data suggest that epitopes such as HTQNT
exposed at the surface of the valve can be recognized by
the anti-streptococcal/anti-myosin mAb 3.B6.
Our studies of mAb 3.B6 are consistent with reports
of antibody deposition on valvular tissue and in
myocardium in RF patients at autopsy (3). Dudding
and Ayoub reported anti–group A carbohydrate anti-
bodies persistently elevated in patients with valvulitis
(9), and surgical removal of inflamed valves resulted in
a significant decrease in levels of anti–group A carbohy-
drate antibodies present in serum (40). We demonstrat-
ed previously that murine anti-streptococcal antibodies
recognized valvular endothelium (41). Collectively,
these studies suggest that antibodies reactive with
valvular tissue may be present in rheumatic carditis
patients and that the valve may serve as a source of anti-
gen to maintain the presence of these autoantibodies. If
autoantibody-mediated damage to endothelium occurs,
the endothelial cells would become activated and upreg-
ulate expression of cell adhesion molecules that allow
inflammatory cells to enter the valve. It is possible that
autoantibodies induced after streptococcal infection
may be responsible for initiation of valvular inflamma-
tion. The discovery of mAb 3.B6 is the first evidence, to
our knowledge, of a human anti-myosin/anti-strepto-
coccal mAb that reacts with the valve surface and under-
lying matrix and that is cytotoxic for human endothe-
lial cells. The study provides important insights into the
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Figure 8
(a) Cytotoxic activity of human mAb 3.B6 on HUVE cells. HUVE cells
were isolated from three umbilical cords and pooled as described (28).
Then, mAb 3.B6 and control mAb 1.C8 (human IgM anti-streptococ-
cal/anti-myosin antibody) were tested at 10 m g/mL. Percentage of cyto-
toxicity was determined by the formula: % lysis = [(test release – spon-
taneous release)/ (maximum release – spontaneous release)] · 100.
Spontaneous release was measured using IMDM without antibody, and
maximum release was measured using 1 N HCl. (b) Cytotoxic activity
of mAb 3.B6 on four primary HUVE cell lines that were isolated from
different umbilical cords. Monoclonal antibody 3.B6 induced cytotox-
icity (gray bars) and no cytotoxicity observed by isotype control mAb
1.C8 (open bars). Percentage of cytotoxicity was determined by the for-
mula as in a. Spontaneous release was measured using IMDM without
antibody, and maximum release was measured using 1 N HCl.
possible mechanism by which valvular damage might
occur during RF. The hypothesis that pathogenic and
cross-reactive autoantibodies can be generated by bac-
terial or foreign antigens is an important concept in
autoimmunity (17, 42, 43).
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